The results from Prognoscan and Kaplan–Meier plotter databases showed that MYL9 expression correlated significantly with prognosis in lung cancer, breast cancer, colorectal cancer, brain glioma, prostate cancer, especially ovarian cancer and gastric cancer. This evidence concerns the gene MYL9 and prostate carcinoma.